Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia

作者：Bo Cai, Yi Wang, Yangyang Lei, Yan‐Ping Shi, Qi‐Yun Sun, Jian‐Hui Qiao, Kai‐Xun Hu, Yaqing Lei, Bingxia Li, Tie-Qiang Liu, Zhiqing Liu, Bo Yao, Xuecong Zhao, Xiaofei Li, Wen Zhao, Xiujie Feng, Anli Xie, Xin Ning, Mingxing Feng, Weiwei Zhao, Jiayue Guo, Hui‐Sheng Ai, Chang-Lin Yu, Mei Guo · 发表于：Stem Cells Translational Medicine · 年份：2022 · DOI：10.1093/stcltm/szac066 · 被引用次数：4 · 研究领域：CAR-T cell therapy research、Acute Lymphoblastic Leukemia research、Hematopoietic Stem Cell Transplantation

Post-remission strategies for patients with acute lymphoblastic leukemia (ALL) are limited to the multiagent chemotherapy and allogeneic stem cell transplant (allo-SCT), and cellular therapies are seldom involved. Although chemotherapy combined with mismatched granulocyte colony-stimulating factor mobilized peripheral blood mononuclear cell infusion (microtransplant, MST) has been studied in patients with acute myeloid leukemia, its efficacy in ALL is still undetermined. We enrolled 48 patients receiving hyper-CVAD-based MST between July 1, 2009, and January 31, 2018. No acute or chronic graft-versus-host disease occurred in patients receiving MST. Four-year overall survival (OS) and leukemia-free survival (LFS) were 62% and 35%, respectively, and the 4-year relapse rate was 65%. No patient experienced non-relapse mortality. Subgroup analysis showed that OS rates were comparable between groups with different age, risk stratification, minimal residual disease status prior to MST and immunophenotype. Adult patients tended to achieve better 4-year LFS (62% vs. 26%, P = .058) and lower hematologic relapse rate (38% vs. 74%, P = .058) compared with adolescent and young adult patients. Donor chimerism/microchimerism was detectable ranging from 0.002% to 42.78% in 78% (42/54) available samples within 14 days after each infusion and at 3 months or one year after the last cell infusion. Multivariate analyses demonstrated that white blood cells <30 × 109/L at diagnosis and sufficient h...